FDA delays ruling on AstraZeneca drug after negative adcomm vote - Fierce Biotech
Regulation
The FDA has delayed its ruling on an AstraZeneca breast cancer drug following a negative advisory committee vote, demanding more data before it will act. This creates an overhang on AZN's pipeline narrative at a time when the stock was benefiting from a string of approval wins, setting up asymmetric downside risk if the delay drags or expands to other assets.
0 reads·0 theses
Angle
↓ SHORT-5% target+3% stop3-6 weeks or until FDA sets new PDUFA date
Short AZN into the FDA delay overhang — negative adcomm vote + more-data demand signals multi-month limbo that chips away at the premium baked into pipeline momentum.